{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:22:45Z","timestamp":1786990965000,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ijtb.2024.10.009","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:25:01Z","timestamp":1730463901000},"page":"S43-S49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Pharmacokinetic drug-drug interaction between first-line anti-TB and anti-diabetic drugs in patients with tuberculosis and diabetes mellitus"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8038-8702","authenticated-orcid":false,"given":"Mary","family":"Rebecca Yowaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Vilvamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bharathiraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Thiruvengadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ponnuraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Vijayalakshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lavanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Hemanth Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2024.10.009_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187967","article-title":"Association between diabetes mellitus and active tuberculosis: a systematic review and metaanalysis","volume":"12","author":"Al-Rifai","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2024.10.009_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1086\/519841","article-title":"The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis","volume":"45","author":"Alisjahbana","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2024.10.009_bib3","doi-asserted-by":"crossref","first-page":"ofw126","DOI":"10.1093\/ofid\/ofw126","article-title":"Diabetes reduces the rate of sputum culture conversion in patients with newly diagnosed multidrug-resistant tuberculosis","volume":"3","author":"Salindri","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijtb.2024.10.009_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-9-81","article-title":"The impact of diabetes on tuberculosis treatment outcomes: a systematic review","volume":"9","author":"Baker","year":"2011","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.ijtb.2024.10.009_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01383-18","article-title":"Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment","volume":"62","author":"Alfarisi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2024.10.009_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-016-2132-z","article-title":"Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus","volume":"73","author":"Kumar","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijtb.2024.10.009_bib7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/507543","article-title":"Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes","volume":"43","author":"Nijland","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2024.10.009_bib8","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1128\/AAC.01067-15","article-title":"Clinical pharmacokinetics of rifampin in patients with tuberculosis and type 2 diabetes mellitus: association with biochemical and immunological parameters","volume":"59","author":"Medellin-Garibay","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2024.10.009_bib9","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1128\/AAC.01345-13","article-title":"Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus","volume":"57","author":"Babalik","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2024.10.009_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tube.2014.10.013","article-title":"Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients","volume":"95","author":"Chang","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijtb.2024.10.009_bib11","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/AAC.06059-11","article-title":"Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV","volume":"56","author":"Requena-Mendez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2024.10.009_bib12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1128\/AAC.00447-09","article-title":"Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes","volume":"54","author":"Ruslami","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2024.10.009_bib13","first-page":"650","article-title":"Diabetes and pulmonary tuberculosis","volume":"24","author":"Banyai","year":"1931","journal-title":"Am Rev Tubercul"},{"key":"10.1016\/j.ijtb.2024.10.009_bib14","series-title":"Williams' Textbook of Endocrinology","year":"2003"},{"issue":"3","key":"10.1016\/j.ijtb.2024.10.009_bib15","first-page":"730","article-title":"Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients","volume":"105","author":"Lindsey","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2024.10.009_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1067\/mcp.2001.115822","article-title":"Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide","volume":"69","author":"Niemi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2024.10.009_bib17","article-title":"Annual report","year":"2020"},{"issue":"4","key":"10.1016\/j.ijtb.2024.10.009_bib18","first-page":"231","article-title":"A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine","volume":"36","author":"Hemanth Kumar","year":"2004","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"10.1016\/j.ijtb.2024.10.009_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3126\/saarctb.v9i1.6960","article-title":"Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in plasma","volume":"9","author":"Hemanth","year":"2012","journal-title":"SAARC J Tuberc Lung Dis HIV\/AIDS"},{"issue":"1","key":"10.1016\/j.ijtb.2024.10.009_bib20","first-page":"119","article-title":"A validated high performance liquid chromatography method for the determination of metformin in human plasma and its application to pharmacokinetic study","volume":"2","author":"Mary Rebecca","year":"2019","journal-title":"Chromatogr Sep Tech J"},{"issue":"1","key":"10.1016\/j.ijtb.2024.10.009_bib21","first-page":"570","article-title":"Dosage frequency of premixed aspart insulin: clinical correlates of three-dose","volume":"57","author":"Kalra","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ijtb.2024.10.009_bib22","unstructured":"Sheng-Wei Pan, Yung-Feng Yen, Yu Ru Kou, et al. The Risk of TB in Patients with Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment."},{"issue":"9","key":"10.1016\/j.ijtb.2024.10.009_bib24","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.5588\/ijtld.16.0048","article-title":"Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India","volume":"20","author":"Hemanth Kumar","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"11","key":"10.1016\/j.ijtb.2024.10.009_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01383-18","article-title":"Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment","volume":"62","author":"Alfarisi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijtb.2024.10.009_bib26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciz380","article-title":"Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes","volume":"70","author":"Ramachandran","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2024.10.009_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2251-6581-11-28","article-title":"Diabetes and tuberculosis: a review of the role of optimal glycemic control","volume":"11","author":"Niazi","year":"2012","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.ijtb.2024.10.009_bib28","series-title":"Theory and Practice","first-page":"554","article-title":"Oral hypoglycemic agents. Ellenberg and Rifkins's diabetes mellitus","author":"Lebovitz","year":"1990"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570724002373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570724002373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:09:29Z","timestamp":1747746569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570724002373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":27,"alternative-id":["S0019570724002373"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2024.10.009","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic drug-drug interaction between first-line anti-TB and anti-diabetic drugs in patients with tuberculosis and diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}